Valencia GA, Rioja P, Morante Z, Araujo JM, Vallejos HD, Guerra H, Gomez HL. PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report. World J Clin Oncol 2021; 12(8): 702-711 [PMID: 34513603 DOI: 10.5306/wjco.v12.i8.702]
Corresponding Author of This Article
Guillermo Arturo Valencia, MD, Medical Assistant, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Angamos Este Avenue 2520, Surquillo, Lima 15000, Peru. guillermo.valencia.mesias@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Aug 24, 2021; 12(8): 702-711 Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.702
PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report
Guillermo Arturo Valencia, Patricia Rioja, Zaida Morante, Jhajaira M Araujo, Heberth Daniel Vallejos, Henry Guerra, Henry L Gomez
Guillermo Arturo Valencia, Patricia Rioja, Zaida Morante, Henry L Gomez, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima 15000, Peru
Jhajaira M Araujo, Escuela de Medicina Humana, Universidad Privada San Juan Bautista, Lima 15067, Peru
Heberth Daniel Vallejos, Department of Medical Oncology, Russian Scientific Center of Radiology and Radiotherapy, Konkovo 117485, Moscow, Russia
Henry Guerra, Department of Pathology, Instituto Nacional de Enfermedades Neoplásicas, Lima 15000, Peru
Author contributions: Valencia GA wrote the paper and collected data; All the authors analyzed the data and approve the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this manuscript, also the accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guillermo Arturo Valencia, MD, Medical Assistant, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Angamos Este Avenue 2520, Surquillo, Lima 15000, Peru. guillermo.valencia.mesias@gmail.com
Received: May 10, 2021 Peer-review started: May 10, 2021 First decision: June 5, 2021 Revised: June 18, 2021 Accepted: July 12, 2021 Article in press: July 12, 2021 Published online: August 24, 2021 Processing time: 105 Days and 3.6 Hours
Abstract
BACKGROUND
Currently, the detection of PIK3CA mutations is of special interest in personalized medicine because it is frequently found in triple-negative breast cancer (TNBC). The PI3KCA mutation is an independent negative prognostic factor for survival in metastatic breast cancer, and its prognostic value in liquid biopsy as a biomarker of treatment and early relapse is under investigation, both for metastatic disease and neoadjuvant scenario with curative intent.
CASE SUMMARY
A 54-year-old female patient with TNBC clinical stage IIIA, who, after receiving neoadjuvant chemotherapy (based on anthracyclines and taxanes), surgery, radiotherapy, and adjuvant capecitabine, was detected with a PI3KCA mutation in tissue and peripheral blood (ctDNA in liquid biopsy). After 10 mo, the patient had disease relapse of left cervical node disease.
CONCLUSION
The detection of PIK3CA mutation in TNBC after neoadjuvant treatment might be associated with early relapse or rapid disease progression.
Core Tip: This case report evaluates the detection of a PIK3CA mutation in liquid biopsy and tumor tissue in a patient with locally-advanced triple-negative breast cancer after receiving conventional oncological therapy and its association with early relapse and progression disease. This case highlights the importance of detecting the PIK3CA mutation as a potential biomarker of early relapse. In addition, the PIK3CA mutation could lead to additional interventions to detect metastatic disease earlier in the follow-up. There is limited information of liquid biopsy studies after surgery. Furthermore, there is very limited data about trials of PIK3CA mutations in Peruvian patients with non-metastatic breast cancer.